Free Trial
NASDAQ:KNTE

Kinnate Biopharma (KNTE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.64
$2.68
50-Day Range
$2.45
$2.66
52-Week Range
$1.04
$7.18
Volume
2.81 million shs
Average Volume
418,678 shs
Market Capitalization
$125.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.15

Kinnate Biopharma MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
207.5% Upside
$8.15 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.51) to ($1.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.22 out of 5 stars

Medical Sector

321st out of 917 stocks

Biotechnology Industry

2nd out of 9 stocks

KNTE stock logo

About Kinnate Biopharma Stock (NASDAQ:KNTE)

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

KNTE Stock News Headlines

KNTE Kinnate Biopharma Inc.
Obama’s DNC coup
As we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In fact, according to Tucker Carlson, in private even "Obama is telling people Biden can't win, and he is therefore in favor of an open convention."
Obama’s DNC coup
As we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In fact, according to Tucker Carlson, in private even "Obama is telling people Biden can't win, and he is therefore in favor of an open convention."
Kinnate Biopharma just downgraded at William Blair, here's why
See More Headlines
Receive KNTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/11/2023
Today
7/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:KNTE
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.15
High Stock Price Target
$24.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+207.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-116,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.06 per share

Miscellaneous

Free Float
27,532,000
Market Cap
$125.13 million
Optionable
Optionable
Beta
1.38
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

KNTE Stock Analysis - Frequently Asked Questions

How were Kinnate Biopharma's earnings last quarter?

Kinnate Biopharma Inc. (NASDAQ:KNTE) issued its earnings results on Thursday, May, 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.73).

When did Kinnate Biopharma IPO?

Kinnate Biopharma (KNTE) raised $170 million in an initial public offering on Thursday, December 3rd 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO.

Who are Kinnate Biopharma's major shareholders?

Kinnate Biopharma's top institutional investors include Equitec Proprietary Markets LLC. Insiders that own company stock include Orbimed Advisors Llc, Carl L Gordon and Richard Thomas Williams.
View institutional ownership trends
.

This page (NASDAQ:KNTE) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners